Literature DB >> 7397626

Desmoplastic nevus: a distinct histologic variant of mixed spindle cell and epithelioid cell nevus.

R J Barr, R V Morales, J H Graham.   

Abstract

From a series of 75 cases of mixed spindle cell and epithelioid cell nevi, 14 were designated as desmoplastic nevi. Junctional activity, theque formation, and pigmentation were uncommon features. As a result, desmoplastic nevi may be confused with a variety of fibrohistiocytic lesions. Well defined intranuclear invaginations of cytoplasm occurred in 12 cases, and were helpful in differentiating desmoplastic nevi from these lesions. Desmoplastic malignant melanoma must also be considered in the microscopic differential diagnosis, but distinguishing features of desmoplastic melanoma include the presence of preexisting lentiginous melanoma, and necrosis of tumor cells and collagen. Desmoplastic nevus was compared to the ordinary variants of mixed spindle cell and eipthelioid cell nevus in an attempt to define etiologic factors responsible for a desmoplastic reaction. No satisfactory explanation could be found since the clinical variables examined were not statistically different.

Entities:  

Mesh:

Year:  1980        PMID: 7397626     DOI: 10.1002/1097-0142(19800801)46:3<557::aid-cncr2820460323>3.0.co;2-l

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

Review 1.  Problematic pigmented lesions: approach to diagnosis.

Authors:  S L Edwards; K Blessing
Journal:  J Clin Pathol       Date:  2000-06       Impact factor: 3.411

2.  Desmoplastic Melanocytic Nevus of Oral Mucosa.

Authors:  Douglas D Damm; Craig B Fowler; David P Schmidt
Journal:  Head Neck Pathol       Date:  2016-01-08

Review 3.  [Hypopigmented melanocytic tumors with spindle cells. A review].

Authors:  M Hantschke
Journal:  Pathologe       Date:  2007-11       Impact factor: 1.011

Review 4.  The Spectrum of Spitz Melanocytic Lesions: From Morphologic Diagnosis to Molecular Classification.

Authors:  Tiffany W Cheng; Madeline C Ahern; Alessio Giubellino
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.